Erasca (ERAS) is down about 4.4% as the market re-prices risk ahead of a near-term clinical update for ERAS-0015. On April 21, 2026, the company filed an update narrowing the expected timing for initial Phase 1 monotherapy data from its ERAS-0015 studies (AURORAS-1 and JYP0015M101) to no later than mid-May 2026, tightening prior guidance that pointed more broadly to the first half of 2026.

A tighter window for a first-in-human oncology data release can pull speculative buying forward, but it also increases “event risk” for holders because the next move may hinge on the quality of early efficacy and safety signals. After a strong run into a defined catalyst date, it’s common to see de-risking and profit-taking—especially in clinical-stage biotech—until investors see details on response durability, dose levels, and tolerability.

The key swing factor is what the mid-May release shows in RAS-mutant solid tumors: any confirmed responses, how responses track by mutation and tumor type, and whether adverse events remain manageable as dose escalation progresses. Investors will also focus on whether the data package supports a clear expansion strategy (e.g., cohort selection, combination plans, and timelines) and whether the company signals additional milestones beyond this readout.